Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a varie...

Descripción completa

Detalles Bibliográficos
Autores principales: Carta, Anna R., Pisanu, Augusta, Carboni, Ezio
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096077/
https://www.ncbi.nlm.nih.gov/pubmed/21603186
http://dx.doi.org/10.4061/2011/689181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096077/
https://www.ncbi.nlm.nih.gov/pubmed/21603186
http://dx.doi.org/10.4061/2011/689181

Ejemplares similares